What's Happening?
Caristo Diagnostics is presenting new findings at the Society of Cardiovascular Computed Tomography (SCCT) 2026, highlighting its AI-powered technologies for coronary inflammation and plaque analysis. The presentations include three abstracts nominated
for the SCCT Young Investigator Award, showcasing the use of FAI-Score on non-contrast cardiac CT for enhanced cardiovascular risk stratification. The findings from the ORFAN registry demonstrate the prognostic value of AI-enabled coronary inflammation imaging, supporting Caristo's CaRi-Plaque and CaRi-Heart technologies. These advancements aim to improve cardiovascular risk assessment and patient management.
Why It's Important?
AI-driven technologies like Caristo's FAI-Score offer significant improvements in cardiovascular risk assessment, potentially leading to earlier detection and better management of heart disease. By enhancing the accuracy of risk stratification, these technologies can help identify patients at higher risk of cardiovascular events, allowing for more targeted interventions. The integration of AI in medical imaging represents a shift towards more personalized and precise healthcare, with the potential to improve outcomes and reduce healthcare costs.
